Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

Part of paid clinical trials in Sacramento, California.

Sponsor
University of California, Davis
Study ID
NCT06101277
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ablative local therapy — DEVICE
    Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

Study Details

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

Key Dates

Start date
Oct 5, 2023
Status verified
Jan 2025
Primary completion
Dec 5, 2025
Completion
Jan 5, 2031

Study Design

Enrollment
300 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ablative local therapy
    Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

Primary Outcome Measure

Number of participants with controlled disease [ Time Frame: 3 months from the first day of ablative local therapy ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, DavisSacramentoCalifornia95817
Selina Laqui, MD, PhD
[email protected]
916-734-0565
Edward Kim, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Sacramento, CA

By condition
Colorectal cancerEsophageal cancerGastric cancer
By specialty
OncologyGI oncology
By research site
University of California, Davis· Sacramento, CA

Related Studies